Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $51.37 USD
Change Today -0.31 / -0.60%
Volume 2.1M
SNY On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
EN Paris
Frankfurt
Frankfurt
NASDAQ GM
As of 8:04 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi-adr (SNY) Key Developments

Innate Pharma S.A. Enters Collaboration Agreement with Sanofi on ADC Using Site-Specific Conjugation Tech

Innate Pharma SA announced that it has entered into a collaboration agreement with Sanofi to apply Innate Pharma's site-specific conjugation technology to the development of new Antibody Drug Conjugates or ADC. Sanofi-Aventis Recherche & Développement, the French R&D affiliate of Sanofi, will evaluate site-specific payload conjugation to enhance ADC pharmacokinetics, efficacy and safety and has the option to enter into a licencing agreement with Innate Pharma on this technology. Other terms of the agreement are undisclosed. Innate Pharma's coupling technology uses bacterial transglutaminase (BTG) enzyme. It aims to address the heterogeneity associated with traditional ADC coupling technologies which limits the therapeutic index of antibody conjugates. With Innate Pharma's technology, a single point mutation in the antibody's heavy chain generates either two or four specific enzyme-recognition sites, and linkers have been optimized to couple quantitatively at these positions.

Schrodinger Signs Drug Discovery Collaboration with Sanofi

Schrodinger signed a multi-year early drug discovery collaboration with Sanofi. Under the contract, Schrodinger will offer target analysis and validation to lead identification and lead optimisation for around ten drug discovery programmes. Schrodinger is to receive up to USD 120 million, which includes preclinical milestones. A new enterprise informatics system will also facilitate real-time collaboration between computational designers and medicinal chemists and will serve as the communications and project management platform for researchers across both firms.

Sanofi Announces Executive Changes

Sanofi has appointed Guido Businger as its new general director. Businger is replacing Fabrizio Guidi, who headed up Sanofi's subsidiary in Turkey. Businger, who has been working at Sanofi in Switzerland since 2004, was most recently head of the neurology division for Germany, Austria and Switzerland.

Ministry of Health Saudi Arabia Signs Cooperation Agreement with Sanofi

The Ministry of Health has entered into a cooperation agreement with Sanofi. The agreement is aimed at helping health care professionals with continuous training for diabetes education in primary care sector, medical research in the area of diabetes and good clinical practice (GCP) training program. Sanofi is partnering up with the MoH and other authorities focusing on continuous medical education for primary care physicians, medical research particularly in type 2 diabetes and GCP training program for health care professionals.

Selecta Biosciences, Inc., JDRF and Sanofi Extends Collaboration to Develop Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

Selecta Biosciences, Inc., and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. This collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas. Selectas proprietary tolerogenic SVP products show potential to re-educate the immune system to stop or suppress pro-inflammatory responses against a specific antigen, thereby halting the undesirable immune reaction without causing harmful global immune suppression common with general immune system modulating drugs. As part of their collaboration, JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic. This next phase of the SVP development program has been structured as a grant award to Selecta in order to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells. JDRF has a strategic research plan designed to deliver a sustained stream of new, life-changing therapies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNY:US $51.37 USD -0.31

SNY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $295.37 USD -1.68
Amgen Inc $165.97 USD +2.39
Bayer AG €137.95 EUR +1.44
Gilead Sciences Inc $100.66 USD -0.72
GlaxoSmithKline PLC 1,576 GBp -5.50
View Industry Companies
 

Industry Analysis

SNY

Industry Average

Valuation SNY Industry Range
Price/Earnings 25.9x
Price/Sales 3.3x
Price/Book 2.0x
Price/Cash Flow 16.4x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.